Ilse Roodink, Maartje van Erp, Andra Li, Sheila Potter, Sander M J van Duijnhoven, Milou Smits, Arthur J Kuipers, Bert Kazemier, Bob Berkeveld, Ellen van Geffen, Britte S de Vries, Danielle Rijbroek, Bianca Boers, Sanne Meurs, Wieger Hemrika, Alexandra Thom, Barry N Duplantis, Roland A Romijn, Jeremy S Houser, Jennifer L Bath, Yasmina N Abdiche
Therapeutic antibodies (Abs) which act on a broader range of epitopes may provide more durable protection against the genetic drift of a target, typical of viruses or tumors. When these Abs exist concurrently on the targeted antigen, several mechanisms of action (MoAs) can be engaged, boosting therapeutic potency. This study selected combinations of four and five Abs with non- or partially overlapping epitopes to the SARS-CoV-2 spike glycoprotein, on or outside the crucial receptor binding domain (RBD), to offer resilience to emerging variants and trigger multiple MoAs...
March 13, 2024: Biomedicines